Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
December 7, 2021
Assignee:
Amolyt Pharma
Inventors:
Thomas Delale, Stephane Milano, Thierry Abribat, David Clemmons
Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.
Type:
Grant
Filed:
February 5, 2018
Date of Patent:
March 16, 2021
Assignee:
Amolyt Pharma
Inventors:
David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
© 2024 Justia
